Exact raises $73.4M; Quest buys Humana's testing biz;

 @FierceMedDev: Edwards wins Japanese nod for next-gen Sapien valve. Story | Follow @FierceMedDev

 @DamianFierce: Miss our ADA 2013 coverage? Diabetes news from Medtronic and J&J. | Follow @DamianFierce

 @MichaelGFierce: FDA approved Lombard's Aorflex delivery system, used with its Aorfix stent. Looking to launch this year. More | Follow @MichaelGFierce

> Fresh off raising $100 million, Valeritas is touting study results showing patients using its V-Go insulin delivery device reported improved glycemic control compared to other technologies. News

> Quest Diagnostics ($DGX) has completed its buyout of Humana's ($HUM) toxicology and clinical laboratory business. More

> In a study of 36 patients, Sorin's Reply 200 pacemakers beat out standard methods in measuring the severity of sleep apnea. Results

> Exact Sciences ($EXAS) wrapped up its stock offering, raising a net $73.4 million to market its Cologuard cancer test. Item

> Good Start Genetics has received approval to launch its sequencing-based carrier screening test in New York. News

Biotech News

 @FierceBiotech: Troubled AstraZeneca models a new industry R&D tie-up as setbacks mount. Story | Follow @FierceBiotech

 @JohnCFierce: Sandoz bulls ahead with full slate of PhIII biosimilar studies. News | Follow @JohnCFierce

 @RyanMFierce: PFE shares software for biotech drug research to pharma rivals like GSK, Roche and others. Story | Follow @RyanMFierce

 @EmilyMFierce:  Our special ADA 2013 issue, via @RyanMFierce: Here | Follow @EmilyMFierce

> FDA clamps partial hold on Cell Therapeutics trial after patient dies. News

> KKR scoops up global CRO PRA in $1.3B buyout deal. More

> Sanofi chief threatens R&D cutbacks unless EMA retreats on open data plan. News

Pharma News

 @FiercePharma: CX, that's 7 trials of 5 biosims for Novartis ... Novartis starts PhIII trial of biosimilar of Amgen's Enbrel. Report | Follow @FiercePharma

 @EricPFierce: Has down-home Paula become the 'Deen' of bad publicity for Novo Nordisk? Item | Follow @EricPFierce

 @CarlyHFierce: Shoutout to FierceBiotech in First Manhattan's letter to Vivus shareholders. Letter | Story | Follow @CarlyHFierce

> Russia's Pharmstandard eyes buyers for $2.5B OTC drug business. More

> Proxy challenger scoffs at Vivus as annual meeting nears. Report

> Reported Form 483 may explain Ranbaxy not getting Diovan to market. Story

CRO News

> Icon, Clintec launch grad programs for clinical research. Article

> CRS signs on with Bayer for early trials. Story

> Novotech reaches into Hong Kong, Philippines. News

> inVentiv taps PatientsLikeMe for trial recruitment. Report

Biotech IT News

> Roche designs online software for sequencing business. Story

> FDA taps India's GVK for database support in drug recycling. More

> Pfizer shares software for biotech drug research with pharma rivals. News

> Scientists follow 'Facebook' strategy to corral cancer Big Data. Story

> PatientsLikeMe seals CRO deal for online trial recruitment. Article